GlassScriptPhysician profile
Andrew James Parchman
NPI 1497935316
$1,984.99
in general payments reported to CMS, 2019-2025
36 companies · $390 in 2025
The $390 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $70.31 · 2021: $55.97 · 2022: $113 · 2023: $544 · 2024: $543 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,460 · Education: $16.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,460.37 |
| Education | $16.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $200.45 | 2022-2025 | |
| Genentech USA, INC. | $165.50 | 2019-2023 | Lunsumio, Polivy |
| Tempus Ai, INC | $160.88 | 2024 | |
| Pfizer INC. | $154.03 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $121.98 | 2023-2025 | Calquence, Tagrisso |
| Intuitive Surgical, INC. | $118.41 | 2019 | |
| Galvanize Therapeutics, INC | $116.19 | 2023 | Aliya System |
| Seagen INC. | $77.72 | 2023 | Padcev |
| Amgen INC. | $77.07 | 2022-2023 | Kyprolis |
| Merck Sharp & Dohme LLC | $76.97 | 2020-2025 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $63.98 | 2020-2025 | Opdivo |
| Astellas Pharma US INC | $60.49 | 2020-2023 | Padcev |
| Aveo Pharmaceuticals, INC. | $60.20 | 2024 | |
| Lilly USA, LLC | $48.26 | 2021-2024 | Jaypirca, Retevmo, Verzenio |
| Emd Serono, INC. | $45.28 | 2023 | Tepmetko |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $32.00 | 2023 | Epkinly, Imbruvica |
| Abbvie INC. | $31.25 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $30.42 | 2021 | |
| Mirati Therapeutics, INC. | $29.80 | 2023-2024 | Krazati |
| Daiichi Sankyo INC. | $28.35 | 2025 | Datroway |
| Gilead Sciences, INC. | $24.75 | 2021-2023 | Trodelvy |
| Incyte Corporation | $23.67 | 2024 | Pemazyre, Monjuvi, Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $22.78 | 2024 | Fruzaqla |
| Accord Healthcare, INC. | $22.46 | 2025 | |
| Springworks Therapeutics, INC. | $20.25 | 2024 | Ogsiveo |
| Jazz Pharmaceuticals INC. | $19.89 | 2024 | |
| Immunogen, INC. | $18.81 | 2024 | Elahere |
| Stemline Therapeutics INC. | $17.66 | 2025 | Orserdu |
| Myovant Sciences INC. | $17.39 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.30 | 2023 | |
| Array Biopharma INC | $16.92 | 2025 | Mektovi, Lorbrena, Braftovi |
| Servier Pharmaceuticals LLC | $16.68 | 2023 | |
| Kite Pharma, INC. | $16.64 | 2025 | Yescarta |
| Puma Biotechnology, INC. | $16.46 | 2023 | |
| Glaxosmithkline, LLC. | $14.10 | 2025 | Ojjaara |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Parchman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.